SATB1 and prostate cancer: In conclusion, we demonstrated that our Score containing SATB1 expression, examined by immunohistochemical analysis in a multiple sample approach, combined with genomic instability and GS is a predictor for prognosis in prostate cancer potentially outperforming risk stratifications in current use.